Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ostrom, 2019, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016, Neuro Oncol, 21, v1, 10.1093/neuonc/noz150
Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol., 131, 803, 10.1007/s00401-016-1545-1
Brat, 2020, cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas, Acta Neuropathol., 139, 603, 10.1007/s00401-020-02127-9
Leece, 2017, Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007, Neuro Oncol., 19, 1553, 10.1093/neuonc/nox091
Davis, 2020, Glioblastoma multiforme incidence in Canada and the US in comparison with England 1995–2015, Neuro Oncol., 22, 301, 10.1093/neuonc/noz203
Philips, Brain Tumours: Rise in Glioblastoma Multiforme Incidence in England 1995–2015 Suggests an Adverse Environmental or Lifestyle Factor, J Environ Public Health, 2018, 7910754
Philips, Authors’ comment on “Brain tumours: rise in glioblastoma multiforme incidence in England 1995–2015 suggests an adverse environmental or lifestyle factor.”, J Environ Public Health., 2018, 2170208
Ostrom, 2019, Risk factors for childhood and adult primary brain tumors, Neuro Oncol., 21, 1357, 10.1093/neuonc/noz123
Ranger, 2014, Familial syndromes associated with intracranial tumours: a review, Childs Nerv Syst., 30, 47, 10.1007/s00381-013-2309-z
Vijapura, 2017, Genetic syndromes associated with central nervous system tumors, Radiographics., 37, 258, 10.1148/rg.2017160057
Jonsson, 2019, Genomic correlates of disease progression and treatment response in prospectively characterized gliomas, Clin Cancer Res., 25, 5537, 10.1158/1078-0432.CCR-19-0032
Melin, 2017, Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors, Nat Genet., 49, 789, 10.1038/ng.3823
Labreche, 2018, Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci, Acta Neuropathol., 135, 743, 10.1007/s00401-018-1825-z
Jung, 2019, Emerging intersections between neuroscience and glioma biology, Nat Neurosci., 22, 1951, 10.1038/s41593-019-0540-y
Gimple, 2019, Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer, Genes Dev., 33, 591, 10.1101/gad.324301.119
Jackson, 2019, Mechanisms of immunotherapy resistance: lessons from glioblastoma, Nat Immunol., 20, 1100, 10.1038/s41590-019-0433-y
Neftel, 2019, An integrative model of cellular states, plasticity, and genetics for glioblastoma, Cell, 178, 835, 10.1016/j.cell.2019.06.024
Bi, 2020, Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets, Nat Rev Cancer., 20, 57, 10.1038/s41568-019-0226-5
Sampson, 2020, Brain immunology and immunotherapy in brain tumours, Nat Rev Cancer., 20, 12, 10.1038/s41568-019-0224-7
Arvanitis, 2020, The blood-brain barrier and blood-tumour barrier in brain tumours and metastases, Nat Rev Cancer., 20, 26, 10.1038/s41568-019-0205-x
Lee, 2018, Human glioblastoma arises from subventricular zone cells with low-level driver mutations, Nature., 560, 243, 10.1038/s41586-018-0389-3
Cancer Genome Atlas Research Network, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature., 455, 1061, 10.1038/nature07385
Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science., 321, 1807, 10.1126/science.1164382
Barthel, 2018, Reconstructing the molecular life history of gliomas, Acta Neuropathol., 135, 649, 10.1007/s00401-018-1842-y
Sturm, 2012, Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma, Cancer Cell., 22, 425, 10.1016/j.ccr.2012.08.024
Brennan, 2013, The somatic genomic landscape of glioblastoma, Cell., 155, 462, 10.1016/j.cell.2013.09.034
Ceccarelli, 2016, Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma, Cell., 164, 550, 10.1016/j.cell.2015.12.028
Wang, 2017, Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment, Cancer Cell., 32, 42, 10.1016/j.ccell.2017.06.003
Frattini, 2018, A metabolic function of FGFR3-TACC3 gene fusions in cancer, Nature., 553, 222, 10.1038/nature25171
Sturm, 2014, Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge, Nat Rev Cancer., 14, 92, 10.1038/nrc3655
Capper, 2018, DNA methylation-based classification of central nervous system tumours, Nature., 555, 469, 10.1038/nature26000
Kim, 2015, Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution, Genome Res., 25, 316, 10.1101/gr.180612.114
Körber, 2019, Evolutionary trajectories of IDHWT glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis, Cancer Cell., 35, 692, 10.1016/j.ccell.2019.02.007
Draaisma, 2020, Molecular evolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study, J Clin Oncol, 38, 81, 10.1200/JCO.19.00367
Touat, 2020, Mechanisms and therapeutic implications of hypermutation in gliomas, Nature., 580, 517, 10.1038/s41586-020-2209-9
Hunter, 2006, A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy, Cancer Res., 66, 3987, 10.1158/0008-5472.CAN-06-0127
Johnson, 2014, Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma, Science., 343, 189, 10.1126/science.1239947
Turner, 2017, Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity, Nature., 543, 122, 10.1038/nature21356
deCarvalho, 2018, Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma, Nat Genet., 50, 708, 10.1038/s41588-018-0105-0
Barthel, 2019, Longitudinal molecular trajectories of diffuse glioma in adults, Nature., 576, 112, 10.1038/s41586-019-1775-1
Patel, 2014, Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, Science., 344, 1396, 10.1126/science.1254257
Sottoriva, 2013, Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics, Proc Natl Acad Sci U S A., 110, 4009, 10.1073/pnas.1219747110
Francis, 2014, EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing, Cancer Discov., 4, 956, 10.1158/2159-8290.CD-13-0879
Snuderl, 2011, Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma, Cancer Cell., 20, 810, 10.1016/j.ccr.2011.11.005
Szerlip, 2012, Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response, Proc Natl Acad Sci U S A., 109, 3041, 10.1073/pnas.1114033109
Miller, 2019, Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid, Nature., 565, 654, 10.1038/s41586-019-0882-3
Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med., 352, 997, 10.1056/NEJMoa043331
World Health Organization., 2016, Histological Classification of Tumors of The Central Nervous System
Korshunov, 2018, Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis, Brain Pathol., 28, 656, 10.1111/bpa.12566
Brat, 2018, cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”, Acta Neuropathol., 136, 805, 10.1007/s00401-018-1913-0
Tesileanu, 2019, Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria, Neuro Oncol, 10.1093/neuonc/noz126.067
Horbinski, 2013, What do we know about IDH1/2 mutations so far, and how do we use it?, Acta Neuropathol., 125, 621, 10.1007/s00401-013-1106-9
Capper, 2010, Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors, Brain Pathol., 20, 245, 10.1111/j.1750-3639.2009.00352.x
DeWitt, 2017, Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations, Neuro Oncol., 19, 1640, 10.1093/neuonc/nox120
Unruh, 2016, Mutant IDH1 and thrombosis in gliomas, Acta Neuropathol., 132, 917, 10.1007/s00401-016-1620-7
Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med., 352, 987, 10.1056/NEJMoa043330
Gilbert, 2013, Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial, J Clin Oncol., 31, 4085, 10.1200/JCO.2013.49.6968
Weller, 2018, Where does O6 -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?, Cancer., 124, 1316, 10.1002/cncr.31244
Hegi, 2015, Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter—still a dilemma?, Neuro Oncol., 17, 1425, 10.1093/neuonc/nov198
Quillien, 2012, Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients, Cancer., 118, 4201, 10.1002/cncr.27392
Bady, 2012, MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status, Acta Neuropathol., 124, 547, 10.1007/s00401-012-1016-2
Hegi, 2019, MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of 4 clinical trials, Clin Cancer Res., 25, 1809, 10.1158/1078-0432.CCR-18-3181
Wick, 2014, MGMT testing—the challenges for biomarker-based glioma treatment, Nat Rev Neurol., 10, 372, 10.1038/nrneurol.2014.100
Weller, 2017, European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, Lancet Oncol., 18, e315, 10.1016/S1470-2045(17)30194-8
Ly, 2020, Imaging of central nervous system tumors based on the 2016 World Health Organization Classification, Neurol Clin., 38, 95, 10.1016/j.ncl.2019.08.004
Chaichana, 2014, Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma, Neuro Oncol., 16, 113, 10.1093/neuonc/not137
Sanai, 2011, An extent of resection threshold for newly diagnosed glioblastomas, J Neurosurg., 115, 3, 10.3171/2011.2.JNS10998
Ellingson, 2015, Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials, Neuro Oncol., 17, 1188
Hu, 2012, Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma, AJNR Am J Neuroradiol., 33, 69, 10.3174/ajnr.A2743
Sadeghi, 2008, Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies, AJNR Am J Neuroradiol., 29, 476, 10.3174/ajnr.A0851
Wesseling, 1994, Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme. Computer-assisted image analysis of whole-tumor sections, J Neurosurg., 81, 902, 10.3171/jns.1994.81.6.0902
Kickingereder, 2014, Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging, Radiology., 272, 843, 10.1148/radiol.14132740
Lee, 2018, Clinical value of vascular permeability estimates using dynamic susceptibility contrast MRI: improved diagnostic performance in distinguishing hypervascular primary CNS lymphoma from glioblastoma, AJNR Am J Neuroradiol., 39, 1415
Suh, 2019, MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: a systematic review and meta-analysis, J Magn Reson Imaging., 50, 560, 10.1002/jmri.26602
Law, 2004, Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade, AJNR Am J Neuroradiol., 25, 746
Gharzeddine, 2019, MR perfusion and MR spectroscopy of brain neoplasms, Radiol Clin North Am., 57, 1177, 10.1016/j.rcl.2019.07.008
Sugahara, 1999, Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas, J Magn Reson Imaging., 9, 53, 10.1002/(SICI)1522-2586(199901)9:1<53::AID-JMRI7>3.0.CO;2-2
Hayashida, 2006, Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity, AJNR Am J Neuroradiol., 27, 1419
Higano, 2006, Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis, Radiology., 241, 839, 10.1148/radiol.2413051276
Guo, 2002, Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics, Radiology., 224, 177, 10.1148/radiol.2241010637
Lu, 2019, Diagnostic performance of DWI for differentiating primary central nervous system lymphoma from glioblastoma: a systematic review and meta-analysis, Neurol Sci., 40, 947, 10.1007/s10072-019-03732-7
Oz, 2014, Clinical proton MR spectroscopy in central nervous system disorders, Radiology., 270, 658, 10.1148/radiol.13130531
Albert, 2016, Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas, Neuro Oncol., 18, 1199, 10.1093/neuonc/now058
Suchorska, 2018, The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors, Q J Nucl Med Mol Imaging, 62, 267, 10.23736/S1824-4785.18.03090-X
Law, 2019, Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0, Eur J Nucl Med Mol Imaging., 46, 540, 10.1007/s00259-018-4207-9
Wen, 2010, Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group, J Clin Oncol., 28, 1963, 10.1200/JCO.2009.26.3541
Wen, 2017, Response assessment in neuro-oncology clinical trials, J Clin Oncol., 35, 2439, 10.1200/JCO.2017.72.7511
Ellingson, 2017, Modified criteria for radiographic response assessment in glioblastoma clinical trials, Neurotherapeutics., 14, 307, 10.1007/s13311-016-0507-6
Wick, 2016, Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma, Neuro Oncol., 18, 1434, 10.1093/neuonc/now091
Okada, 2015, Immunotherapy response assessment in neuro-oncology: a report of the RANO working group, Lancet Oncol., 16, e534, 10.1016/S1470-2045(15)00088-1
Kickingereder, 2019, Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study, Lancet Oncol., 20, 728, 10.1016/S1470-2045(19)30098-1
Chang, 2019, Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement, Neuro Oncol., 21, 1412, 10.1093/neuonc/noz106
Pace, 2017, European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma, Lancet Oncol., 18, e330, 10.1016/S1470-2045(17)30345-5
Vecht, 1994, Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day, Neurology., 44, 675, 10.1212/WNL.44.4.675
Lim-Fat, 2019, Letter: when less is more: dexamethasone dosing for brain tumors, Neurosurgery., 85, E607, 10.1093/neuros/nyz186
Lee, 2016, Corticosteroids for peritumoral edema: time to overcome our addiction?, Neuro Oncol., 18, 1191, 10.1093/neuonc/now167
Ly, 2017, clinical relevance of steroid use in Neuro-Oncology, Curr Neurol Neurosci Rep., 17, 5, 10.1007/s11910-017-0713-6
Pitter, 2016, Corticosteroids compromise survival in glioblastoma, Brain., 139, 1458, 10.1093/brain/aww046
Taplitz, 2018, Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update, J Clin Oncol., 36, 3043, 10.1200/JCO.18.00374
Chang, 2005, Patterns of care for adults with newly diagnosed malignant glioma, JAMA., 293, 557, 10.1001/jama.293.5.557
Forsyth, 2003, Prophylactic anticonvulsants in patients with brain tumour, Can J Neurol Sci., 30, 106, 10.1017/S0317167100053361
Glantz, 1996, A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors, Neurology., 46, 985, 10.1212/WNL.46.4.985
Glantz, 2000, Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology., 54, 1886, 10.1212/WNL.54.10.1886
Kuijlen, 1996, Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis, Seizure., 5, 291, 10.1016/S1059-1311(96)80023-9
Pulman, 2013, Antiepileptic drugs as prophylaxis for post-craniotomy seizures, Cochrane Database Syst Rev., 2, CD007286
Wu, 2013, A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors, J Neurosurg., 118, 873, 10.3171/2012.12.JNS111970
Schiff, 2015, Medical management of brain tumors and the sequelae of treatment, Neuro Oncol., 17, 488, 10.1093/neuonc/nou304
Venkatesh, 2019, Electrical and synaptic integration of glioma into neural circuits, Nature., 573, 539, 10.1038/s41586-019-1563-y
Venkataramani, 2019, Glutamatergic synaptic input to glioma cells drives brain tumor progression, Nature., 573, 532, 10.1038/s41586-019-1564-x
Grossman, 2009, Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial, J Clin Oncol., 27, 4155, 10.1200/JCO.2008.21.6895
Laws, 2003, Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project, J Neurosurg., 99, 467, 10.3171/jns.2003.99.3.0467
Czap, 2019, Thrombotic complications in gliomas, Semin Thromb Hemost., 45, 326, 10.1055/s-0039-1687892
Levin, 1993, Complications of therapy for venous thromboembolic disease in patients with brain tumors, Neurology., 43, 1111, 10.1212/WNL.43.6.1111
Gerber, 2006, Management of venous thromboembolism in patients with primary and metastatic brain tumors, J Clin Oncol., 24, 1310, 10.1200/JCO.2005.04.6656
Mantia, 2017, Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin, Blood., 129, 3379, 10.1182/blood-2017-02-767285
Norden, 2012, Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients, J Neurooncol., 106, 121, 10.1007/s11060-011-0642-1
Lee, 2003, Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, N Engl J Med., 349, 146, 10.1056/NEJMoa025313
Carney, 2019, Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors, J Thromb Haemost., 17, 72, 10.1111/jth.14336
Raskob, 2018, Edoxaban for the treatment of cancer-associated venous thromboembolism, N Engl J Med., 378, 615, 10.1056/NEJMoa1711948
Young, 2018, Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D), J Clin Oncol., 36, 2017, 10.1200/JCO.2018.78.8034
Perry, 2010, PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma, J Thromb Haemost., 8, 1959, 10.1111/j.1538-7836.2010.03973.x
Le Rhun, 2018, Associations of anticoagulant use with outcome in newly diagnosed glioblastoma, Eur J Cancer., 101, 95, 10.1016/j.ejca.2018.06.029
Gehring, 2015, Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma, Neurooncol Pract., 2, 20
Tucha, 2000, Cognitive deficits before treatment among patients with brain tumors, Neurosurgery., 47, 324, 10.1097/00006123-200008000-00011
Armstrong, 2012, Practical strategies for management of fatigue and sleep disorders in people with brain tumors, Neuro Oncol., 14, iv65, 10.1093/neuonc/nos210
Armstrong, 2017, Sleep-wake disturbance in patients with brain tumors, Neuro Oncol., 19, 323
Boele, 2013, The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial, Neuro Oncol., 15, 1420, 10.1093/neuonc/not102
Butler, 2007, A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy, Int J Radiat Oncol Biol Phys., 69, 1496, 10.1016/j.ijrobp.2007.05.076
Rapp, 2015, Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial, J Clin Oncol., 33, 1653, 10.1200/JCO.2014.58.4508
Lee, 2016, A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy, Neuro Oncol., 18, 849, 10.1093/neuonc/now007
Rooney, 2011, Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma, J Clin Oncol., 29, 4307, 10.1200/JCO.2011.34.8466
Ruden, 2011, Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma, J Clin Oncol., 29, 2918, 10.1200/JCO.2011.34.9852
Derr, 2009, Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma, J Clin Oncol., 27, 1082, 10.1200/JCO.2008.19.1098
Gilbert, 2014, A randomized trial of bevacizumab for newly diagnosed glioblastoma, N Engl J Med., 370, 699, 10.1056/NEJMoa1308573
Stupp, 2009, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol., 10, 459, 10.1016/S1470-2045(09)70025-7
Lamborn, 2008, Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas, Neuro Oncol., 10, 162, 10.1215/15228517-2007-062
Wu, 2010, Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma, Neuro Oncol., 12, 164, 10.1093/neuonc/nop019
Clarke, 2011, Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?, Neuro Oncol., 13, 1118, 10.1093/neuonc/nor110
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), 2019, Central Nervus System Cancers
Stupp, 2017, Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial, JAMA., 318, 2306, 10.1001/jama.2017.18718
Herrlinger, 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial, Lancet., 393, 678, 10.1016/S0140-6736(18)31791-4
Perry, 2017, Short-course radiation plus temozolomide in elderly patients with glioblastoma, N Engl J Med., 376, 1027, 10.1056/NEJMoa1611977
Wick, 2012, Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial, Lancet Oncol., 13, 707, 10.1016/S1470-2045(12)70164-X
Malmström, 2012, Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial, Lancet Oncol., 13, 916, 10.1016/S1470-2045(12)70265-6
Wick, 2017, Lomustine and bevacizumab in progressive glioblastoma, N Engl J Med., 377, 1954, 10.1056/NEJMoa1707358
Perry, 2010, Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study, J Clin Oncol., 28, 2051, 10.1200/JCO.2009.26.5520
Weller, 2015, MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial, Clin Cancer Res., 21, 2057, 10.1158/1078-0432.CCR-14-2737
Vogelbaum, 2012, Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group, Neurosurgery, 70, 234, 10.1227/NEU.0b013e318223f5a7
Eigenbrod, 2014, Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients, Acta Neurochir (Wien)., 156, 1427, 10.1007/s00701-014-2073-1
Sahm, 2012, Addressing diffuse glioma as a systemic brain disease with single-cell analysis, Arch Neurol., 69, 523, 10.1001/archneurol.2011.2910
Grabowski, 2014, Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma, J Neurosurg., 121, 1115, 10.3171/2014.7.JNS132449
Stummer, 2006, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial, Lancet Oncol., 7, 392, 10.1016/S1470-2045(06)70665-9
Kreth, 2013, Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy, Ann Oncol., 24, 3117, 10.1093/annonc/mdt388
Marko, 2014, Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery, J Clin Oncol., 32, 774, 10.1200/JCO.2013.51.8886
Brown, 2016, Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis, JAMA Oncol., 2, 1460, 10.1001/jamaoncol.2016.1373
Ringel, 2016, Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection, Neuro Oncol., 18, 96, 10.1093/neuonc/nov145
Suchorska, 2016, Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial, Neuro Oncol., 18, 549, 10.1093/neuonc/nov326
Ellingson, 2018, Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma, Neuro Oncol., 20, 1240, 10.1093/neuonc/noy053
De Witt Hamer, 2012, Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis, J Clin Oncol., 30, 2559, 10.1200/JCO.2011.38.4818
Jenkinson, 2018, Intraoperative imaging technology to maximise extent of resection for glioma, Cochrane Database Syst Rev, 1, CD012788
Stummer, 2011, Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article, J Neurosurg., 114, 613, 10.3171/2010.3.JNS097
Gulati, 2011, The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma, World Neurosurg., 76, 572, 10.1016/j.wneu.2011.06.014
Brem, 1995, Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group, Lancet., 345, 1008, 10.1016/S0140-6736(95)90755-6
Westphal, 2003, A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neuro Oncol., 5, 79, 10.1093/neuonc/5.2.79
Balana, 2020, A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01), Neuro-Oncol., 10.1093/neuonc/noaa107
Blumenthal, 2017, Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG, Neuro Oncol., 19, 1119, 10.1093/neuonc/nox025
Gramatzki, 2017, Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma, Neurology., 88, 1422, 10.1212/WNL.0000000000003809
Chinot, 2014, Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma, N Engl J Med., 370, 709, 10.1056/NEJMoa1308345
Stupp, 2019, Improving survival in molecularly selected glioblastoma, Lancet., 393, 615, 10.1016/S0140-6736(18)33211-2
Niyazi, 2016, ESTRO-ACROP guideline “target delineation of glioblastomas”, Radiother Oncoly, 118, 35, 10.1016/j.radonc.2015.12.003
Chang, 2019, Neoplasms of the central nervous system., Cancer: Principles and Practice of Oncology, 11th ed, 1568
Kruser, 2019, NRG brain tumor specialists consensus guidelines for glioblastoma contouring, J Neurooncol., 143, 157, 10.1007/s11060-019-03152-9
Wernicke, 2016, Glioblastoma: Radiation treatment margins, how small is large enough?, Pract Radiat Oncol., 6, 298, 10.1016/j.prro.2015.12.002
Ellsworth, 2018, Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors, Adv Radiat Oncol., 3, 512, 10.1016/j.adro.2018.08.014
Grossman, 2011, Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide, Clin Cancer Res., 17, 5473, 10.1158/1078-0432.CCR-11-0774
Ellingson, 2017, Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape, J Neurooncol., 134, 495, 10.1007/s11060-017-2375-2
Strauss, 2019, Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis, Radiol Clin North Am., 57, 1199, 10.1016/j.rcl.2019.07.003
Haider, 2020, Towards a standard pathological and molecular characterization of recurrent glioma in adults: a RANO effort, Neuro Oncol, 22, 450, 10.1093/neuonc/noz233
Wick, 2018, Glioblastoma in elderly patients: solid conclusions built on shifting sand?, Neuro Oncol., 20, 174, 10.1093/neuonc/nox133
Roa, 2004, Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial, J Clin Oncol., 22, 1583, 10.1200/JCO.2004.06.082
Roa, 2015, International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme, J Clin Oncol., 33, 4145, 10.1200/JCO.2015.62.6606
Stupp, 2012, NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality, Eur J Cancer., 48, 2192, 10.1016/j.ejca.2012.04.011
Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol., 27, 4733, 10.1200/JCO.2008.19.8721
Hovey, 2017, Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial, Neurooncol Pract., 4, 171
Levin, 2011, Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system, Int J Radiat Oncol Biol Phys., 79, 1487, 10.1016/j.ijrobp.2009.12.061
Brandes, 2016, Nitrosoureas in the management of malignant gliomas, Curr Neurol Neurosci Rep., 16, 13, 10.1007/s11910-015-0611-8
Batchelor, 2013, Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma, J Clin Oncol., 31, 3212, 10.1200/JCO.2012.47.2464
Taal, 2014, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol., 15, 943, 10.1016/S1470-2045(14)70314-6
Brandes, 2016, AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma, Neuro Oncol., 18, 1304, 10.1093/neuonc/now035
Lombardi, 2019, Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial, Lancet Oncol., 20, 110, 10.1016/S1470-2045(18)30675-2
Straube, 2019, A second course of radiotherapy in patients with recurrent malignant gliomas: clinical data on re-irradiation, prognostic factors, and usefulness of digital biomarkers, Curr Treat Options Oncol., 20, 71, 10.1007/s11864-019-0673-y
Scoccianti, 2018, Re-irradiation as salvage treatment in recurrent glioblastoma: a comprehensive literature review to provide practical answers to frequently asked questions, Crit Rev Oncol Hematol., 126, 80, 10.1016/j.critrevonc.2018.03.024
Shi, 2018, Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: a secondary analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525, Int J Radiat Oncol Biol Phys., 100, 38, 10.1016/j.ijrobp.2017.08.038
Tsien, 2019, ACTR-232. NRG Oncology RTOG 1205: randomized phase II trial of concurrent bevacizumab and re-irradiation versus bevacizumab alone as treatment for recurrent glioblastoma, Neuro Oncol., 21, vi 20, 10.1093/neuonc/noz175.075
Le Rhun, 2019, Molecular targeted therapy of glioblastoma, Cancer Treat Rev., 80, 101896, 10.1016/j.ctrv.2019.101896
Horbinski, 2019, The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients, Neuro Oncol., 21, 1498, 10.1093/neuonc/noz119
van den Bent, 2009, Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034, J Clin Oncol., 27, 1268, 10.1200/JCO.2008.17.5984
Weller, 2017, Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial, Lancet Oncol., 18, 1373, 10.1016/S1470-2045(17)30517-X
Reardon, 2017, Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma, Neuro Oncol., 19, 965
van den Bent, 2017, Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study, Cancer Chemother Pharmacol., 80, 1209, 10.1007/s00280-017-3451-1
Lassman, 2019, A randomized, double-blind, placebo-controlled phase 3 trial of depatuxizumab mafodotin (ABT-414) in Epidermal Growth Factor Receptor (EGFR) Amplified (Amp) Newly Diagnosed Glioblastoma (nGBM), Neuro Oncol, 21, vi17, 10.1093/neuonc/noz175.064
van den Bent, 2019, INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma, Neuro Oncol.
Reardon, 2014, Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges, Neuro Oncol, 16, viii7, 10.1093/neuonc/nou232
Kaley, 2018, BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study, J Clin Oncol., JCO2018789990
Wen, 2019, Updated efficacy and safety of dabrafenib plus trametinib in patients with recurrent/refractory BRAF V600E–mutated high-grade glioma (HGG) and low-grade glioma (LGG), Neuro Oncol., 21
Behling, 2016, Frequency of BRAF V600E mutations in 969 central nervous system neoplasms, Diagn Pathol., 11, 55, 10.1186/s13000-016-0506-2
Drilon, 2019, TRK inhibitors in TRK fusion-positive cancers, Ann Oncol., 30, viii23, 10.1093/annonc/mdz282
Arrillaga-Romany, 2019, Single agent ONC201 in previously-treated, progressive adult H3 K27M-mutant glioma, Neuro Oncol., 21, vi20, 10.1093/neuonc/noz175.077
Chi, 2019, Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201, J Neurooncol., 145, 97, 10.1007/s11060-019-03271-3
Lasorella, 2017, FGFR-TACC gene fusions in human glioma, Neuro Oncol., 19, 475
Killela, 2013, TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal, Proc Natl Acad Sci U S A., 110, 6021, 10.1073/pnas.1303607110
Sandmann, 2015, Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial, J Clin Oncol., 33, 2735, 10.1200/JCO.2015.61.5005
Wirsching, 2018, Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial, Ann Oncol., 29, 1423, 10.1093/annonc/mdy120
Ellingson, 2017, Diffusion MRI phenotypes predict overall survival benefit from anti-VEGF monotherapy in recurrent glioblastoma: converging evidence from phase II trials, Clin Cancer Res., 23, 5745, 10.1158/1078-0432.CCR-16-2844
Wick, 2014, A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma, Clin Cancer Res., 20, 6304, 10.1158/1078-0432.CCR-14-0951-T
Wick, 2016, Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082), Clin Cancer Res., 22, 4797, 10.1158/1078-0432.CCR-15-3153
Cloughesy, 2008, Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma, PLoS Med., 5, e8, 10.1371/journal.pmed.0050008
Chinnaiyan, 2018, A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913, Neuro Oncol., 20, 666, 10.1093/neuonc/nox209
Lassman, 2019, Infigratinib (BGJ398) in FGFR altered recurrent malignant glioma: a multicenter phase II study, Neuro Oncology., 21, vi20, 10.1093/neuonc/noz175.076
Wen, 2019, Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial, J Clin Oncol., 37, 741, 10.1200/JCO.18.01207
Cloughesy, 2018, Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy, Neuro Oncol., 20, 249, 10.1093/neuonc/nox151
Wen, 2018, Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy, Neuro Oncol., 20, 249, 10.1093/neuonc/nox154
Wick, 2019, N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma, Neuro Oncol., 21, 95, 10.1093/neuonc/noy161
Alexander, 2019, Individualized screening trial of innovative glioblastoma therapy (INSIGhT): a Bayesian adaptive platform trial to develop precision medicines for patients with glioblastoma, J Clin Oncol Precis Oncol., 10.1200/PO.18.00071
Alexander, 2018, Adaptive global innovative learning environment for glioblastoma: GBM AGILE, Clin Cancer Res., 24, 737, 10.1158/1078-0432.CCR-17-0764
Wen, 2014, Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02, Neuro Oncol., 16, 567, 10.1093/neuonc/not247
Osuka, 2017, Overcoming therapeutic resistance in glioblastoma: the way forward, J Clin Invest., 127, 415, 10.1172/JCI89587
Lassman, 2019, Efficacy and safety of selinexor in recurrent glioblastoma, Neuro Oncol., 21, iii3, 10.1093/neuonc/noz126.008
Carruthers, 2018, Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells, Cancer Res., 78, 5060, 10.1158/0008-5472.CAN-18-0569
Bao, 2006, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature., 444, 756, 10.1038/nature05236
Yap, 2019, The DNA damaging revolution: PARP inhibitors and beyond, Am Soc Clin Oncol Educ Book., 39, 185, 10.1200/EDBK_238473
Pilié, 2019, State-of-the-art strategies for targeting the DNA damage response in cancer, Nat Rev Clin Oncol., 16, 81, 10.1038/s41571-018-0114-z
Beckta, 2019, Targeting DNA repair in gliomas, Curr Opin Neurol., 32, 878, 10.1097/WCO.0000000000000760
Gupta, 2016, Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma, J Natl Cancer Inst., 108, 10.1093/jnci/djv369
Gupta, 2014, Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts, Clin Cancer Res., 20, 3730, 10.1158/1078-0432.CCR-13-3446
Gupta, 2018, PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma: impact of blood–brain barrier and molecular heterogeneity, Front Oncol., 8, 670, 10.3389/fonc.2018.00670
Jackson, 2019, Temozolomide sensitizes MGMT-deficient tumor cells to ATR inhibitors, Cancer Res., 79, 4331, 10.1158/0008-5472.CAN-18-3394
Venneti, 2017, Metabolic reprogramming in brain tumors, Annu Rev Pathol., 12, 515, 10.1146/annurev-pathol-012615-044329
Agnihotri, 2016, PINK1 is a negative regulator of growth and the warburg effect in glioblastoma, Cancer Res., 76, 4708, 10.1158/0008-5472.CAN-15-3079
Agnihotri, 2019, Ketoconazole and posaconazole selectively target HK2-expressing glioblastoma cells, Clin Cancer Res., 25, 844, 10.1158/1078-0432.CCR-18-1854
Villa, 2016, An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers, Cancer Cell., 30, 683, 10.1016/j.ccell.2016.09.008
Lim, 2018, Current state of immunotherapy for glioblastoma, Nat Rev Clin Oncol., 15, 422, 10.1038/s41571-018-0003-5
Reardon, 2016, Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model, Cancer Immunol Res., 4, 124, 10.1158/2326-6066.CIR-15-0151
Zeng, 2013, Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas, Int J Radiat Oncol Biol Phys., 86, 343, 10.1016/j.ijrobp.2012.12.025
Belcaid, 2014, Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model, PLoS One., 9, e101764, 10.1371/journal.pone.0101764
Fecci, 2007, Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function, Clin Cancer Res., 13, 2158, 10.1158/1078-0432.CCR-06-2070
Wei, 2019, Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target, J Clin Invest., 129, 137, 10.1172/JCI121266
Wainwright, 2014, Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors, Clin Cancer Res., 20, 5290, 10.1158/1078-0432.CCR-14-0514
Brandes, 2016, A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma, Neuro Oncol., 18, 1146, 10.1093/neuonc/now009
Butowski, 2016, Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study, Neuro Oncol., 18, 557, 10.1093/neuonc/nov245
Reardon, 2020, Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial, JAMA Oncol
Liau, 2018, First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma, J Transl Med., 16, 142, 10.1186/s12967-018-1507-6
Lang, 2018, Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma, J Clin Oncol., 36, 1419, 10.1200/JCO.2017.75.8219
Desjardins, 2018, Recurrent glioblastoma treated with recombinant poliovirus, N Engl J Med., 379, 150, 10.1056/NEJMoa1716435
Chiocca, 2019, Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial, Sci Transl Med., 11, 10.1126/scitranslmed.aaw5680
Wheeler, 2016, Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma, Neuro Oncol., 18, 1137, 10.1093/neuonc/now002
Cloughesy, 2019, TOCA 5: Toca 511 & Toca FC versus standard of care in patients with recurrent high grade glioma
Schreiber, 2011, Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion, Science., 331, 1565, 10.1126/science.1203486
Platten, 2019, Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond, Nat Rev Drug Discov., 18, 379, 10.1038/s41573-019-0016-5
Jackson, 2016, Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination, Clin Cancer Res., 22, 1161, 10.1158/1078-0432.CCR-15-1516
Chongsathidkiet, 2018, Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors, Nat Med., 24, 1459, 10.1038/s41591-018-0135-2
Woroniecka, 2018, T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma, Clin Cancer Res., 24, 4175, 10.1158/1078-0432.CCR-17-1846
Keskin, 2019, Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial, Nature., 565, 234, 10.1038/s41586-018-0792-9
Weller, 2019, Nivolumab versus bevacizumab in patients with recurrent glioblastoima: exploratory analysis of MGMT mathylation status and baseline corticosteroid use, Neuro Oncol, 21, vi12, 10.1093/neuonc/noz175.045
Brown, 2016, Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy, N Engl J Med., 375, 2561, 10.1056/NEJMoa1610497
O’Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med., 9, 10.1126/scitranslmed.aaa0984
Cloughesy, 2018, Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC, Neuro Oncol., 20, 1383, 10.1093/neuonc/noy075
Lawler, 2017, Oncolytic viruses in cancer treatment: a review, JAMA Oncol., 3, 841, 10.1001/jamaoncol.2016.2064
Wen, 2019, Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients With Glioblastoma, Clin Cancer Res., 25, 5799, 10.1158/1078-0432.CCR-19-0261
Hilf, 2019, Actively personalized vaccination trial for newly diagnosed glioblastoma, Nature., 565, 240, 10.1038/s41586-018-0810-y
Bouffet, 2016, Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency, J Clin Oncol., 34, 2206, 10.1200/JCO.2016.66.6552
Johanns, 2016, Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy, Cancer Discov., 6, 1230, 10.1158/2159-8290.CD-16-0575
Keenan, 2019, Genomic correlates of response to immune checkpoint blockade, Nat Med., 25, 389, 10.1038/s41591-019-0382-x
Danilova, 2018, The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity, Cancer Immunol Res., 6, 888, 10.1158/2326-6066.CIR-18-0129
Murray, 2014, Macrophage activation and polarization: nomenclature and experimental guidelines, Immunity., 41, 14, 10.1016/j.immuni.2014.06.008
Mathios, 2016, Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM, Sci Transl Med, 8, 370ra180, 10.1126/scitranslmed.aag2942
Cloughesy, 2019, Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma, Nat Med., 25, 477, 10.1038/s41591-018-0337-7
Schalper, 2019, Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma, Nat Med., 25, 470, 10.1038/s41591-018-0339-5
Forde, 2018, Neoadjuvant PD-1 blockade in resectable lung cancer, N Engl J Med., 378, 1976, 10.1056/NEJMoa1716078
Amaria, 2018, Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma, Nat Med., 24, 1649, 10.1038/s41591-018-0197-1
Bagley, 2018, CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges, Neuro Oncol., 20, 1429, 10.1093/neuonc/noy032
Bagley, 2020, Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions, Pharmacol Ther., 205, 107419, 10.1016/j.pharmthera.2019.107419
Weiss, 2018, NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma, Cancer Res., 78, 1031, 10.1158/0008-5472.CAN-17-1788
Kaufmann, 2014, Glioma virus therapies between bench and bedside, Neuro Oncol., 16, 334, 10.1093/neuonc/not310
Kwiatkowska, 2013, Strategies in gene therapy for glioblastoma, Cancers., 5, 1271, 10.3390/cancers5041271
Chiocca, 2014, Oncolytic viruses and their application to cancer immunotherapy, Cancer Immunol Res., 2, 295, 10.1158/2326-6066.CIR-14-0015
Andtbacka, 2015, Talimogene laherparepvec improves durable response rate in patients with advanced melanoma, J Clin Oncol., 33, 2780, 10.1200/JCO.2014.58.3377
Chiocca, 2019, Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?, Neuro Oncol., 21, 14, 10.1093/neuonc/noy170
Iorgulescu, 2018, Immunotherapy for glioblastoma: going viral, Nat Med., 24, 1094, 10.1038/s41591-018-0142-3
Todo, 2019, Results of phase II clinical trial of oncolytic Herpes virus G47Δ In patients with glioblastoma, Neuro Oncol, 21, vi4, 10.1093/neuonc/noz175.014
Ribas, 2017, Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy, Cell, 170, 1109, 10.1016/j.cell.2017.08.027
Cloughesy, 2016, Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma, Sci Transl Med, 8, 341ra375, 10.1126/scitranslmed.aad9784
Cloughesy, 2020, A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE), Neuro Oncol., 22, 705, 10.1093/neuonc/noz232
Brenner, 2020, Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study, Neuro Oncol., 22, 694, 10.1093/neuonc/noz231
Wen, 2011, It is time to include patients with brain tumors in phase I trials in oncology, J Clin Oncol., 29, 3211, 10.1200/JCO.2011.36.6328
Gounder, 2015, Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors, J Clin Oncol., 33, 3186, 10.1200/JCO.2015.61.1525
Ventz, 2019, Design and evaluation of an external control arm using prior clinical trials and real-world data, Clin Cancer Res., 25, 4993, 10.1158/1078-0432.CCR-19-0820
Stupp, 2014, Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol., 15, 1100, 10.1016/S1470-2045(14)70379-1
Wick, 2010, Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma, J Clin Oncol., 28, 1168, 10.1200/JCO.2009.23.2595
Le Tourneau, 2015, Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial, Lancet Oncol., 16, 1324, 10.1016/S1470-2045(15)00188-6
Rodon, 2019, Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial, Nat Med., 25, 751, 10.1038/s41591-019-0424-4
2019
Vanderbeek, 2018, The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?, Neuro Oncol., 20, 1034, 10.1093/neuonc/noy027
Lee, 2019, Barriers to accrual and enrollment in brain tumor trials [published online ahead of print June 7, 2019], Neuro Oncol.
Welch, 2017, EPID-11. identifying barriers to clinical research: a pilot study to improve access and enrollment to neuro-oncology trials at Columbia University Center Medical Center (CUMC), Neuro Oncol., 19, vi71, 10.1093/neuonc/nox168.289
Lee, 2020, Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients, Neuro Oncol., 22, 601
Murphy, 2015, Review of cranial radiotherapy-induced vasculopathy, J Neurooncol., 122, 421, 10.1007/s11060-015-1732-2
Sarkaria, 2018, Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data, Neuro Oncol., 20, 184, 10.1093/neuonc/nox175
Heffron, 2018, Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels, Neuro Oncol., 20, 307, 10.1093/neuonc/nox179
Vivanco, 2012, Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors, Cancer Discov., 2, 458, 10.1158/2159-8290.CD-11-0284
Wen, 2020, First-in-human phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma, Clin Cancer Res., 26, 1820, 10.1158/1078-0432.CCR-19-2808
Drappatz, 2013, Phase I study of GRN1005 in recurrent malignant glioma, Clin Cancer Res., 19, 1567, 10.1158/1078-0432.CCR-12-2481
Idbaih, 2019, Safety and feasibility of repeated and transient blood-brain barrier disruption by pulsed ultrasound in patients with recurrent glioblastoma, Clin Cancer Res., 25, 3793, 10.1158/1078-0432.CCR-18-3643
Lan, 2017, Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy, Nature., 549, 227, 10.1038/nature23666
Chen, 2012, A restricted cell population propagates glioblastoma growth after chemotherapy, Nature., 488, 522, 10.1038/nature11287
Nathanson, 2014, Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA, Science., 343, 72, 10.1126/science.1241328
Liau, 2017, Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance, Cell Stem Cell, 20, 233, 10.1016/j.stem.2016.11.003
Akhavan, 2013, De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients, Cancer Discov., 3, 534, 10.1158/2159-8290.CD-12-0502
Mai, 2017, Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma, Nat Med., 23, 1342, 10.1038/nm.4418